Pathology of pulmonary hypertension.
The secondary role of pathology in the present clinical management of pulmonary hypertension (PH) reflects to some extent the limitations of the current understanding of the disease. Ample room exists for the diagnostic translation of the pathobiologic studies, with the goal of improving the diagnostic and prognostic power of the pathologic assessment of pulmonary vascular remodeling. This article seeks to show the complementarities of the pathology and pathobiology of PH.
Tuder
Rubin M
RM
Division of Cardiopulmonary Pathology, Johns Hopkins University School of Medicine, 720 Rutland Avenue, Ross Research Building, Baltimore, MD 21217, USA. rtuder@jhmi.edu
Marecki
John C
JC
Richter
Amy
A
Fijalkowska
Iwona
I
Flores
Sonia
S
D017209:Apoptosis / Q000502:physiology; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000502:physiology; D019485:Bone Morphogenetic Proteins / Q000502:physiology; D003094:Collagen / Q000032:analysis; D042783:Endothelial Cells / Q000473:pathology / Q000502:physiology; D004727:Endothelium / Q000473:pathology; D005347:Fibroblasts / Q000502:physiology; D015693:Gene Products, nef / Q000502:physiology; D006801:Humans; D006976:Hypertension, Pulmonary / Q000473:pathology* / Q000503:physiopathology; D006984:Hypertrophy; D007150:Immunohistochemistry; D018836:Inflammation Mediators / Q000502:physiology; D011651:Pulmonary Artery / Q000473:pathology; D014655:Vascular Resistance / Q000502:physiology
D019485:Bone Morphogenetic Proteins; D015693:Gene Products, nef; D018836:Inflammation Mediators; D003094:Collagen; C498218:BMPR2 protein, human; D052006:Bone Morphogenetic Protein Receptors, Type II